Analyst firms · William Blair · JSPR

William Blair JSPR price target and rating history

Jasper Therapeutics Inc. (JSPR) · Health Care

William Blair rates Jasper Therapeutics Inc. (JSPR) Outperform, as of its latest action on Oct 14, 2026. It has published 3 rating actions on JSPR since October 2021, including 0 upgrades and 1 downgrade. Across 3 firms with a JSPR price target in the last 12 months, the median target is $2.

Current rating
Outperform
Price target
Not stated
Median target, all firms
$2
Actions on JSPR
3

Every William Blair rating on JSPR

How other firms rate JSPR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
William BlairOutperformOct 14, 2026
Piper SandlerOverweight$2Aug 12, 2026
TD CowenHoldMay 15, 2026
UBSNeutral$1.50Mar 23, 2026
Rodman & RenshawBuy$17Jan 13, 2026

Questions about William Blair and JSPR

What is William Blair's rating on JSPR?
William Blair rates JSPR Outperform, a bullish rating, as of Oct 14, 2026.
When did William Blair last change its view on JSPR?
On Oct 14, 2026, William Blair resumes coverage at Outperform.
How does William Blair's JSPR target compare with other analysts?
Across 3 firms with a JSPR price target in the last 12 months, the median target is $2.

More JSPR rating histories

All William Blair ratingsJSPR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.